Table 1.
Baseline Parameters
| Variable | All (n=177) | Sorafenib (n=118) | Lenvatinib (n=21) | Atez/Bev (n=38) | Global p-value | p-value Sorafenib vs Atez/Bev | p-value Lenvatinib vs Atez/Bev |
|---|---|---|---|---|---|---|---|
| Age | 66 (58–73) | 66 (58–72) | 67 (61–73) | 68 (59–74) | 0.679 | ||
| Male | 136 (76.8%) | 94 (79.7%) | 12 (57.1%) | 30 (78.9%) | 0.075 | ||
| BMI | 26 (23–30) | 26 (23–29) | 26 (24–30) | 27 (24–30) | 0.985 | ||
| Weight | 81 (72–95) | 80 (74–95) | 75 (72–100) | 84 (71–95) | 0.641 | ||
| ECOG | 0.510 | ||||||
| 0/1 | 133 (75.1%) | 82 (69.5%) | 17 (80.9%) | 34 (89.5%) | |||
| ≥2 | 44 (24.9%) | 36 (30.5%) | 4 (19.0%) | 4 (10.5%) | |||
| Child-Pugh-Class | 0.028 | 0.025 | 1.000 | ||||
| A | 109 (61.6%) | 63 (53.4%) | 16 (76.2%) | 30 (78.9%) | |||
| B/C | 60 (33.9%) | 47 (39.8%) | 5 (23.8%) | 8 (21.1%) | |||
| Unknown | 8 (4.5%) | 8 (6.8%) | 0 | 0 | |||
| Etiology | |||||||
| Presence of Cirrhosis | 150 (84.8%) | 104 (88.1%) | 18 (85.7%) | 28 (73.7%) | 0.099 | ||
| Alcohol | 42 (23.7%) | 29 (24.6%) | 9 (42.9%) | 4 (10.5%) | 0.019 | 0.096 | 0.012 |
| HBV | 30 (17.0%) | 19 (16.1%) | 2 (9.5%) | 9 (23.7%) | 0.351 | ||
| HCV | 47 (26.6%) | 37 (31.4%) | 3 (14.3%) | 7 (18.4%) | 0.118 | ||
| NASH | 31 (17.5%) | 11 (9.3%) | 9 (42.9%) | 11 (29.0%) | 0.000 | 0.009 | 0.426 |
| Other | 38 (21.5%) | 30 (25.4%) | 3 (14.3%) | 5 (13.2%) | 0.194 | ||
| BCLC | 0.000 | 0.002 | <0.001 | ||||
| B | 38 (21.5%) | 21 (17.8%) | 0 | 17 (44.7%) | |||
| C | 138 (78.0%) | 96 (81.4%) | 21 (100.0%) | 21 (55.3%) | |||
| D | 1 (0.6%) | 1 (0.8%) | 0 | 0 | |||
| Macrovascular invasion of main vessel | 51 (28.8%) | 28 (23.7%) | 10 (47.6%) | 13 (34.2%) | 0.359 | ||
| Extrahepatic Metastases | 91 (51.4%) | 62 (52.5%) | 15 (71.4%) | 14 (36.8%) | 0.041 | 0.092 | 0.022 |
| Maximal size of intrahepatic tumor. cm | 6 (3–9) | 6 (4–9) | 6 (4–8) | 5 (3–8) | 0.629 | ||
| Grading | 0.299 | ||||||
| 1 | 14 (7.9%) | 11 (9.3%) | 0 | 3 (7.9%) | |||
| 2 | 67 (37.8%) | 42 (35.6%) | 10 (47.6%) | 15 (39.5%) | |||
| 3 | 21 (11.9%) | 12 (10.2%) | 4 (19.0%) | 5 (13.2%) | |||
| MELD-Score | 8 (7–11) | 9 (7–12) | 7 (6–8) | 8 (8–10) | 0.010 | 0.267 | 0.030 |
| ALBI-Score | 0.007 | 0.009 | 1.000 | ||||
| 1 | 49 (27.7%) | 24 (20.3%) | 8 (38.1%) | 17 (44.7%) | |||
| 2 | 84 (47.5%) | 57 (48.3%) | 11 (52.4%) | 16 (42.1%) | |||
| 3 | 33 (18.6%) | 27 (22.9%) | 1 (4.8%) | 5 (13.2%) | |||
| Crafity-Score | 0.027 | 0.017 | 0.027 | ||||
| 0 | 69 (39.0%) | 39 (33.1%) | 7 (33.3%) | 23 (60.5%) | |||
| 1 | 73 (41.2%) | 49 (41.5%) | 14 (66.7%) | 10 (26.3%) | |||
| 2 | 5 (2.8%) | 4 (3.4%) | 0 | 1 (2.6%) | |||
| AFP-values | 84 (10–1980) | 173 (12–2389) | 140 (13–5061) | 26 (6–402) | 0.173 | ||
| AFP >400ng/mL | 69 (40.8%) | 50 (44.2%) | 10 (47.6%) | 9 (25.7%) | 0.121 | ||
| Previous therapies | |||||||
| Surgery | 52 (29.4%) | 32 (27.1%) | 10 (47.6%) | 10 (26.3%) | 0.149 | ||
| RFA/MWA/HIFU | 14 (7.9%) | 5 (4.2%) | 2 (9.5%) | 7 (18.4%) | 0.019 | 0.019 | 0.611 |
| SIRT | 39 (22.0%) | 23 (19.5%) | 1 (4.8%) | 15 (39.5%) | 0.005 | 0.026 | 0.006 |
| TACE | 68 (38.4%) | 45 (38.1%) | 11 (52.4%) | 12 (31.6%) | 0.291 | ||
| Transplantation | 4 (2.3%) | 3 (2.5%) | 1 (4.8%) | 0 | 0.471 | ||
| TIPS | 13 (7.3%) | 10 (8.5%) | 1 (4.8%) | 2 (5.3%) | 0.717 | ||
| Treated varices at baseline | 71 (40.1%) | 52 (44.1%) | 5 (23.8%) | 14 (36.8%) | 0.198 | ||
| Second Line Therapy | |||||||
| Systemic Second-Line | 48 (27.1%) | 26 (22.0%) | 12 (57.1%) | 10 (26.3%) | <0.001 | 0.001 | 0.627 |
Notes: Numerical data are presented as median with range in parenthesis. Categorial data are presented as absolute frequency with relative frequency in parenthesis.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B; HCV, hepatitis C; NASH, non-alcoholic steatohepatitis; BCLC, Barcelona Clinic Liver Cancer; RFA, Radiofrequency Ablation; MWA, microwave ablation; HIFU, high-intensity focused ultrasound; SIRT, selective internal radiation therapy; TACE, transarterial chemoembolization; TIPS: transjugular intrahepatic portosystemic shunt.